Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

Hidradenitis Suppurativa (HS) is getting increased attention from dermatologists due to its frequent misdiagnosis and ...

Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Incyte’s stock price has taken a hit of more than 11%, despite two Phase III trials investigating its oral small-molecule ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...